Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions
Open Access
- 1 July 2022
- journal article
- review article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 88 (4) , 1203-1228
Abstract
Psychotic phenomena are among the most severe and disruptive symptoms of dementias and appear in 30% to 50% of patients. They are associated with a worse evolution and great suffering to patients and caregivers. Their current treatments obtain limited results and are not free of adverse effects, which are sometimes serious. It is therefore crucial to develop new treatments that can improve this situation. We review available data that could enlighten the future design of clinical trials with psychosis in dementia as main target. Along with an explanation of its prevalence in the common diseases that cause dementia, we present proposals aimed at improving the definition of symptoms and what should be included and excluded in clinical trials. A review of the available information regarding the neurobiological basis of symptoms, in terms of pathology, neuroimaging, and genomics, is provided as a guide towards new therapeutic targets. The correct evaluation of symptoms is transcendental in any therapeutic trial and these aspects are extensively addressed. Finally, a critical overview of existing pharmacological and non-pharmacological treatments is made, revealing the unmet needs, in terms of efficacy and safety. Our work emphasizes the need for better definition and measurement of psychotic symptoms in dementias in order to highlight their differences with symptoms that appear in non-dementing diseases such as schizophrenia. Advances in neurobiology should illuminate the development of new, more effective and safer molecules for which this review can serve as a roadmap in the design of future clinical trials.Keywords
This publication has 245 references indexed in Scilit:
- Efficacy of Memantine for Agitation in Alzheimer’s Dementia: A Randomised Double-Blind Placebo Controlled TrialPLOS ONE, 2012
- Donepezil and Memantine for Moderate-to-Severe Alzheimer's DiseaseNew England Journal of Medicine, 2012
- Feeling of presence in Parkinson's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2011
- Trajectory of Cognitive Decline as a Predictor of Psychosis in Early Alzheimer Disease in the Cardiovascular Health StudyThe American Journal of Geriatric Psychiatry, 2011
- Antipsychotic drugs and risk of venous thromboembolism: nested case-control studyBMJ, 2010
- Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer diseaseNeurology, 2009
- Exposure to antipsychotics and risk of stroke: self controlled case series studyBMJ, 2008
- Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer’s Disease: Phase 1 Outcomes From the CATIE-AD Effectiveness TrialAmerican Journal of Psychiatry, 2008
- Point and 5‐year period prevalence of neuropsychiatric symptoms in dementia: the Cache County StudyInternational Journal of Geriatric Psychiatry, 2007
- The Neuropsychiatric InventoryNeurology, 1994